temozolomide has been researched along with (pPNET) Peripheral Primitive Neuroectodermal Tumors in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Irinotecan and temozolomide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy." | 9.41 | Irinotecan dose schedule for the treatment of Ewing sarcoma. ( Meyers, PA; Slotkin, EK, 2023) |
| "Irinotecan and temozolomide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy." | 5.41 | Irinotecan dose schedule for the treatment of Ewing sarcoma. ( Meyers, PA; Slotkin, EK, 2023) |
| "Advances in the biology of Ewing sarcoma, which continues to be an important cause of mortality, have caused an increase in information in the literature related to the underlying molecular base of the disease and discussions of new treatment approaches." | 1.72 | Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study. ( Aliç, T; Hassa, E, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slotkin, EK | 1 |
| Meyers, PA | 1 |
| Hassa, E | 3 |
| Aliç, T | 3 |
1 review available for temozolomide and (pPNET) Peripheral Primitive Neuroectodermal Tumors
| Article | Year |
|---|---|
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neopl | 2023 |
1 other study available for temozolomide and (pPNET) Peripheral Primitive Neuroectodermal Tumors
| Article | Year |
|---|---|
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |
Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study.
Topics: Child; Cross-Sectional Studies; Humans; Irinotecan; Neuroectodermal Tumors, Primitive, Peripheral; S | 2022 |